Avenue Therapeutics, Inc. Stock price

Equities

ATXI

US05360L3042

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.1475 USD -3.34% Intraday chart for Avenue Therapeutics, Inc. -6.82% -8.39%
Sales 2024 * - Sales 2025 * - Capitalization 6.53M
Net income 2024 * -13M Net income 2025 * -15M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.36 x
P/E ratio 2025 *
-0.4 x
Employees 3
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.12%
More Fundamentals * Assessed data
Dynamic Chart
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy CI
Certain Stock Options of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024. CI
Certain Warrants of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024. CI
Certain Common Stock of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024. CI
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected MT
Top Midday Gainers MT
Avenue Therapeutics Shares Rise 68% After FDA Agreement for Tramadol Study DJ
Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) CI
Maxim Starts Coverage on Avenue Therapeutics with Buy Rating, $0.75 Price Target MT
Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Insider Buy: Avenue Therapeutics MT
Avenue Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Fortress Biotech, Inc. and other investor CI
Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study CI
More news
1 day-3.34%
1 week-6.82%
Current month-2.77%
1 month-2.70%
3 months-10.39%
6 months-78.02%
Current year-8.39%
More quotes
1 week
0.14
Extreme 0.14
0.16
1 month
0.14
Extreme 0.14
0.20
Current year
0.11
Extreme 0.1125
0.35
1 year
0.11
Extreme 0.1125
1.36
3 years
0.11
Extreme 0.1125
113.10
5 years
0.11
Extreme 0.1125
185.10
10 years
0.11
Extreme 0.1125
185.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 22-07-31
Director of Finance/CFO 34 -
Chief Tech/Sci/R&D Officer - 18-08-31
Members of the board TitleAgeSince
Director/Board Member 68 15-02-08
Chairman 66 17-01-31
Director/Board Member 66 15-07-31
More insiders
Date Price Change Volume
24-03-28 0.1475 -3.34% 799,429
24-03-27 0.1526 +1.06% 495,501
24-03-26 0.151 -2.58% 1,145,146
24-03-25 0.155 +2.51% 2,770,774
24-03-22 0.1512 -4.49% 1,584,613

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1475 USD
Average target price
16.38 USD
Spread / Average Target
+11,001.69%
Consensus
  1. Stock
  2. Equities
  3. Stock Avenue Therapeutics, Inc. - Nasdaq